Benzinga · Mar 5, 2026
Wedbush Maintains Outperform on TScan Therapeutics, Raises Price Target to $5
Wedbush analyst David Nierengarten maintains TScan Therapeutics (NASDAQ:TCRX) with a Outperform and raises the price target from $4 to $5.
TC
NASDAQ · TCRX
TScan Therapeutics, Inc.
Healthcare · Biotechnology
$0.32
Down-$0.01 (-3.70%)
Updated Sep 11, 2026, 4:58 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 61.01M
- P/E ratio
- -1.02
- Dividend yield
- 0.00%
- 52-week range
- $0.33 – $1.47
- Volume
- 804.59K
- Avg. volume
- 792.82K
Price performance
TCRX price history
1M range · 0 trading sessions · Daily adjusted prices
TCRX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest TCRX news
The latest Smart Investors Daily articles mentioning TCRX.
Stock researchCompany · Overview
TCRX research
Overview
Company profile and research snapshot.
Company profile
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $7.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 8, 2026 | HC Wainwright & Co. | Neutral | — |
| Sep 3, 2026 | Wedbush | Neutral | — |
| Sep 2, 2026 | Needham | Hold | — |
| Aug 12, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 23, 2026 | Wedbush | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 4, 2026
Earnings Breakdown: TScan Therapeutics Q4
Benzinga · Mar 4, 2026
TScan Therapeutics' Cash And Cash Equivalents Of $152.4M To Provide Cash Runway Into 2H Of 2027
Benzinga · Mar 4, 2026
TScan Therapeutics Q4 2025 EPS $(0.18) Beats $(0.24) Estimate, Sales $2.567M Beat $2.048M Estimate
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
